-
- Kathryn R. Wagner
- Center for Genetic Muscle Disorders, Kennedy Krieger Institute
抄録
<jats:sec> <jats:title>Purpose of review</jats:title> <jats:p>Recent terminations of clinical trials of myostatin inhibitors in muscular dystrophy have raised questions about the predictiveness of mouse models for this therapeutic strategy.</jats:p> </jats:sec> <jats:sec> <jats:title>Recent findings</jats:title> <jats:p>A variety of myostatin inhibitors have been developed for preclinical and clinical studies. These inhibitors have ameliorated the phenotype of many but not all mouse models of muscular dystrophy. However, randomized double-blinded placebo controlled trials in both pediatric and adult muscular dystrophies have, as of yet, not demonstrated functional improvement.</jats:p> </jats:sec> <jats:sec> <jats:title>Summary</jats:title> <jats:p>The present article will review the preclinical promise of myostatin inhibitors, the clinical trial experience to date of these inhibitors in muscular dystrophy, and the potential reasons for the lack of observed translation.</jats:p> </jats:sec>
収録刊行物
-
- Current Opinion in Neurology
-
Current Opinion in Neurology 33 (5), 621-628, 2020-08-25
Ovid Technologies (Wolters Kluwer Health)